Skip to main content
TipRanks
Go Ultimate75% OFF

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) AI Stock Analysis

2 Followers
HK:8049

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

(HKEX:8049)

Select Model
Rating:90Outperform
Price Target:HKD 3.50â–²(22.81% Upside)
Action:reiterated
Date:09/19/26

The stock achieves a robust overall score of 90, primarily driven by its pristine financial foundation and deeply discounted valuation. The company boasts a virtually debt-free balance sheet, phenomenal free cash flow generation, and strong operational profitability. These fundamental strengths are paired with a highly attractive P/E ratio of 4.04, indicating significant undervaluation. Additionally, technical indicators confirm a healthy and sustained upward price trend. The only minor area for improvement is capital efficiency, as the company could better utilize its massive equity base to generate higher shareholder returns.

Positive Factors
Sustained ProfitabilityConsistently high gross and net margins indicate a resilient earnings model and pricing or cost structure. Stable operating profitability provides internal funding capacity, supports reinvestment in pharmaceutical products, and helps the company absorb moderate changes in demand over the next several quarters.
Negative Factors
Cooling Revenue MomentumThe progression from strong earlier expansion to flat, modest, and then slightly negative growth shows that top-line momentum has cooled. Persistent weakness would limit operating leverage, constrain future earnings expansion, and make continued profitability more dependent on cost control.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) vs. iShares MSCI Hong Kong ETF (EWH)

-10%0%10%20%30%40%50%HK:8049+43.22%EWH+9.93%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.60B
Dividend Yield
―
Average Volume (3M)
32.23K
Price to Earnings (P/E)
4.8
Beta (1Y)
0.22
Revenue Growth
0.20%
EPS Growth
24.13%
Country
Hong Kong
Employees
1,107
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio i...

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview

Summary

The company exhibits exceptional financial health, highlighted by consistent revenue growth and robust profit margins in the 17% to 23% range. Its balance sheet is nearly debt-free, and it demonstrates phenomenal cash generation, with free cash flow routinely exceeding net income.

Income Statement

85Very Positive

Balance Sheet

95Very Positive

Cash Flow

90Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.11B901.87M881.16M841.54M841.59M705.46M
Gross Profit938.82M757.67M685.25M584.05M648.03M580.00M
EBITDA332.86M294.19M236.33M226.39M231.43M206.50M
Net Income278.44M198.88M184.25M148.21M193.56M143.28M
Balance Sheet
Total Assets2.73B2.67B2.53B2.32B2.37B2.07B
Cash, Cash Equivalents and Short-Term Investments902.41M681.45M539.03M655.59M1.03B262.25M
Total Debt399.93K400.00K72.40M80.40M400.00K400.00K
Total Liabilities922.64M982.74M901.49M838.44M760.54M618.56M
Stockholders Equity1.81B1.69B1.63B1.48B1.61B1.45B
Cash Flow
Free Cash Flow0300.80M208.63M284.11M192.68M122.25M
Operating Cash Flow0313.24M219.65M315.95M203.99M215.09M
Investing Cash Flow0-229.19M-310.93M109.04M-117.97M-160.61M
Financing Cash Flow0-176.80M-25.01M-186.45M-27.71M-25.20M

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis

Technical Analysis SentimentPositive
Last Price2.85

Price Trends

50DMA2.51Positive
100DMA2.42Positive
200DMA2.24Positive

Market Momentum

MACD0.11Negative
RSI64.33Neutral
STOCH86.03Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.85 is above the 20-day moving average (MA) of 2.72, above the 50-day MA of 2.51, and above the 200-day MA of 2.24, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 64.33 is Neutral, neither overbought nor oversold. The STOCH value of 86.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:8049 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:8049HK:804990OutperformHKD 1.60B4.8415.91%―0.20%24.13%
HK:2348HK:234874OutperformHKD 1.37B4.936.78%7.12%6.55%36.62%
HK:1061HK:106173OutperformHKD 1.05B3.9610.70%6.45%-0.74%-15.21%
HK:2161HK:216173OutperformHKD 1.24B6.0018.70%11.39%6.69%2.45%
HK:2633HK:263370OutperformHKD 1.71B5.9613.26%10.05%-0.47%-0.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2561HK:256138UnderperformHKD 1.38B-4.31-33.42%―――

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%HK:8049HK:1061HK:2161HK:2348HK:2633HK:2561Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8049 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8049Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H2.850.8643.22%
HK:1061Essex Bio-Technology 1.86-2.35-55.87%
HK:2161JBM (Healthcare) Ltd.1.50-1.31-46.58%
HK:2348Dawnrays Pharmaceutical Holdings Ltd.0.89-0.20-18.21%
HK:2633Jacobson Pharma Corporation Limited0.90-0.41-31.45%
HK:2561VISEN Pharmaceuticals11.16-20.40-64.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026